Last updated: February 1, 2026
Summary
DOPTELET (avatrombopag) is an oral thrombopoietin receptor agonist developed by Idorsia Pharmaceuticals, approved primarily for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled for elective procedures. This report synthesizes recent clinical trial activities, regulatory developments, market dynamics, and future projections to aid stakeholders in understanding DOPTELET’s current landscape and growth potential.
Clinical Trials Update
Recent and Ongoing Clinical Trials
| Trial Phase |
Trial ID |
Title / Objective |
Status |
Key Details |
| Phase 3 |
NCT04463487 |
Evaluation of avatrombopag versus placebo in thrombocytopenia associated with CLD |
Completed |
Enrolled 500+ patients; primary endpoints included platelet response (≥50 x 10^9/L) before procedures |
| Phase 2 |
NCT04304973 |
Avatrombopag for immune thrombocytopenia (ITP) |
Active, recruiting |
Focused on ITP indication; preliminary safety and efficacy signals expected Q4 2023 |
| Phase 2 |
NCT04523339 |
Investigating avatrombopag in aplastic anemia |
Active, recruiting |
Aiming to evaluate hematopoietic effects in non-CLD thrombocytopenia |
Key Clinical Data Highlights
-
Efficacy in Thrombocytopenia (CLD):
The pivotal ADAPT trials demonstrated a statistically significant increase in platelet counts, enabling safer surgeries.
- Response Rate: Up to 65% of patients achieved platelet levels ≥50 x 10^9/L.
- Onset of Action: Within 5 days; maintained through the procedure window.
-
Safety Profile:
Generally well tolerated; common adverse events included headache, nausea, and mild elevations in liver enzymes. No significant hepatotoxicity observed.
-
Regulatory Status:
DOPTELET gained FDA approval in November 2018 and EMA approval in 2019 for thrombocytopenia in CLD patients.
Major Clinical Developments
-
Recent Post-Marketing Studies:
An observational study (NCT05054116) assessing real-world safety and efficacy in diverse ethnic populations is ongoing, with interim data confirming safety consistency.
-
Upcoming Trials:
Idorsia announced plans for a Phase 3 trial evaluating DOPTELET in ITP patients (expected initiation Q2 2023), potentially expanding its label.
Market Analysis
Market Size and Segments
| Segment |
Estimated Global Market (2023) |
Projected CAGR (2023-2028) |
Notes |
| Thrombocytopenia in CLD |
$700 million |
7% |
Dominant indication, with stable growth |
| Immune Thrombocytopenia (ITP) |
$250 million |
9% |
Untapped, current clinical trials focus here |
| Aplastic Anemia |
$150 million |
10% |
Emerging, early-stage indications |
Source: EvaluatePharma, 2023.
Competitive Landscape
| Drug |
Mechanism |
Indications |
Market Share (2023) |
Key Features |
| DOPTELET (avatrombopag) |
Thrombopoietin receptor agonist |
CLD thrombocytopenia |
~50% |
Oral, single-agent, once daily |
| Promacta (eltrombopag) |
TPO receptor agonist |
ITP, AH |
~30% |
Oral, requires liver function monitoring |
| Nplate (romiplostim) |
TPO mimetic |
ITP |
~15% |
Injectable, monthly |
Market Entry Barriers and Opportunities
-
Barriers:
- Competition from established agents (Promacta, Nplate).
- Regulatory delays in expanding indications.
- Need for head-to-head trials to consolidate efficacy advantage.
-
Opportunities:
- Expanding approval to ITP based on ongoing clinical trials.
- Growing prevalence of liver disease and thrombocytopenia globally.
- Potential novel indications, e.g., aplastic anemia, multiple myeloma-associated thrombocytopenia.
Regulatory and Reimbursement Trends
-
FDA and EMA:
Maintain favorable position for thrombocytopenia in CLD indications; potential label expansions could improve market scope.
-
Reimbursement Policies:
Increasing reimbursement support aligning with evidence of reduced bleeding complications and procedural safety.
Market Projection
Projection Assumptions
| Parameter |
Assumption |
Source / Rationale |
| Market Growth Rate |
7-10% CAGR (2023-2028) |
Based on current trends in thrombocytopenia management |
| Approval in New Indications |
2024-2025 |
Pending successful phase 3 outcomes |
| Market Penetration |
60% in CLD, 20% in ITP by 2028 |
Derived from competitive analysis |
Forecast Table (2023-2028)
| Year |
Thrombocytopenia in CLD ($ millions) |
ITP Market ($ millions) |
Total Market ($ millions) |
| 2023 |
700 |
250 |
950 |
| 2024 |
749 (+7%) |
273 (+9%) |
1,022 |
| 2025 |
804 (+7.4%) |
298 (+9%) |
1,102 |
| 2026 |
862 (+7.2%) |
324 (+9%) |
1,186 |
| 2027 |
924 (+7%) |
351 (+8.3%) |
1,275 |
| 2028 |
990 (+7%) |
380 (+8.2%) |
1,370 |
Note: Projections are compounded annually, considering emerging indications and market expansion.
Comparison with Competitors
| Feature |
DOPTELET (avatrombopag) |
Promacta (eltrombopag) |
Nplate (romiplostim) |
| Administration |
Oral daily |
Oral daily |
Injectable weekly/monthly |
| Indications |
CLD thrombocytopenia (approved), ITP (investigational) |
ITP, AH |
ITP, others |
| Dosing Flexibility |
Flexible dosing |
Fixed dosing |
Fixed dosing |
| Key Advantages |
Oral, no need for blood monitoring in routine |
Proven efficacy, broader indications |
Established safety profile |
Deepening Insights
Potential for Expanded Indications
- Aplastic anemia: Preliminary data suggests avatrombopag may promote multilineage hematopoiesis.
- Chemotherapy-induced thrombocytopenia: Opportunities remain; ongoing trials could establish efficacy.
- Other chronic disease contexts: Hematological recovery post organ transplantation or in hematological malignancies.
Regulatory & Policy Impacts
- Orphan drug designation could facilitate accelerated approval for rare indications such as aplastic anemia.
- Pricing strategies may need to adapt for expanded indications to optimize market access.
Key Takeaways
- Current Status: DOPTELET remains a pivotal treatment for thrombocytopenia in CLD, with consistent positive clinical trial results and regulatory approval in major markets.
- Market Potential: The global thrombocytopenia market is projected to grow CAGR 7-10% over the next five years, with significant opportunity in ITP and emerging indications.
- Competitive Positioning: DOPTELET’s oral administration offers advantages over injectable alternatives, supporting potential expansion into new therapeutic areas.
- Clinical Pipeline: Ongoing trials in ITP and other thrombocytopenic disorders could lead to label expansions, significantly increasing market share.
- Strategic Outlook: Focused efforts on expanding indications, building real-world evidence, and navigating regulatory pathways could position DOPTELET as a leading agent in thrombopoietic therapies.
FAQs
1. What are the primary clinical benefits of DOPTELET compared to existing thrombopoietic agents?
DOPTELET’s oral administration, rapid platelet response, and favorable safety profile make it convenient and potentially safer for patients, especially in preoperative settings.
2. When is DOPTELET expected to gain approval for additional indications like ITP?
Pending positive results from ongoing Phase 3 trials, regulatory submissions are anticipated in 2024, with potential approval by 2025.
3. How does DOPTELET fit into the treatment hierarchy for thrombocytopenia?
It serves as a targeted therapy primarily for CLD-related thrombocytopenia and is being evaluated for broader indications, providing an alternative to injectable agents.
4. What barriers could impede market growth for DOPTELET?
Competition from established drugs, slow regulatory approvals for new indications, and cost considerations may limit rapid market penetration.
5. How does Idorsia’s strategy influence DOPTELET’s future market success?
Idorsia’s focus on clinical expansion, real-world evidence collection, and proactive regulatory engagement could accelerate adoption and maximize the drug’s market potential.
References
[1] EvaluatePharma. (2023). Market Outlook for Thrombocytopenia Treatments.
[2] FDA. (2018). DOPTELET (avatrombopag) approval announcement.
[3] EMA. (2019). DOPTELET Market Authorization Details.
[4] ClinicalTrials.gov. (2023). List of ongoing and completed avatrombopag trials.
[5] Idorsia Pharmaceuticals. (2023). Corporate Pipeline and Clinical Development Updates.
